Skip to main content

Table 6 Treatment uptake in study cohorts receiving opioid substitution therapy

From: A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region

Author, year % treated (# treated/# of treatment candidates SVR (%) (# with sustained viral response/# treated)
Cournot et al, 2004 31% of antibody+ (23/75) Intent-to-treat: 36% (11/31)1
  47% of RNA+ (23/49)  
  72% of other (23/32)  
Cullen et al, 2007 3% of antibody+ (3/104) NA
  10% of RNA+ (3/29)  
Schulte et al, 20102 9% of antibody+ (26/301) Intent-to-treat: 69% (18/26)
As-treated: 86% (18/21)
Witteck et al, 20112 15% of RNA+ (29/193) Intent-to-treat: 52% (13/25)
  1. Antibody+ = study participants who are hepatitis C antibody-positive
  2. RNA+ = study participants who are hepatitis C RNA-positive
  3. Other = study participants who are hepatitis C RNA-positive and meet additional treatment criteria
  4. 1. Calculated according to the number of treatment outcomes (N=31) rather than the number of patients who initiated therapy (N=23)
  5. 2. Study cohort received heroin maintenance therapy